Literature summary for 3.4.17.20 extracted from

Koldas, M.; Gummus, M.; Seker, M.; Seval, H.; Hulya, K.; Dane, F.; Kural, A.; Gumus, A.; Salepci, T.; Turhal, N.S.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer (2008), Clin. Lung Cancer, 9, 112-115.

Search for more literature for 3.4.17.20

Application

Application	Comment	Organism
medicine	coagulation pathway in patients with non-small-cell lung cancer (NSCLC) is investigated: The TAFI activity, prothrombin fragment 1 + 2 levels, and tissue factor pathway inhibitor activity are significantly higher in patients with lung cancer than in subjects in the control group. There is no statistically significant associations between TAFI activity levels and patient age, sex, body mass index, histopathology, or stage of disease	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q8IWV7	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Synonyms

Synonyms	Comment	Organism
TAFI	-	Homo sapiens
thrombin-activatable fibrinolysis inhibitor	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)